SERANGMHealthcare·Medical Devices#87 in industry

Sera Prognostics, Inc.

Reports in 10d· 2026-05-06

-32.0% · 90d

$2.04

+0.03 (+1.49%)

News

No News Yet

Press releases and SEC filings for SERA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$79.9M

Open$2.06

Prev Close$2.01

Day Range$2.01 – $2.16

52W Range$1.37 – $4.09

Volume6,990

P/E (TTM)—

EPS$-0.67

Dividend Yield—

Beta1.06

Revenue Growth-58.30%

Price Target$5.00(+145.1%)

Next Earnings2026-05-06(10d)

Analyst Ratings

Strong Buy3 analysts

Buy 3Hold 0Sell 0

About

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Healthcare · Medical Devices

71 employees

www.sera.com